Efficacy of Mindfulness in PREventing Progression to Psychosis in Individuals With an Ultra High Risk for Psychosis (EM-PREPS)

March 24, 2026 updated by: Centre Psychothérapique de Nancy
The main objective is to evaluate the efficacy of a group-based mindfulness therapy programme in reducing distress associated with symptoms of UHR (Ultra High Risk) or FEP (first psychotic episode) compared with usual treatment. The secondary objectives were to study the efficacy of a group-based mindfulness intervention: on the reduction of psychotic symptoms; on the maintenance over time (6 months of follow-up) of the efficacy of the intervention on the distress associated with the symptoms of the UHR or PEP state; and on various dimensions associated with care: cognitive functions, anxiety, quality of life.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
270

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • France
      • Brest, France, 29200
        • Centre Hospitalier Universitaire (CHU) de Brest
        • Principal Investigator:
          • Christophe LEMEY, MD
      • Laxou, France, 54520
        • Centre Psychothérapique de Nancy
        • Contact:
        • Principal Investigator:
          • vincent LAPREVOTE, PU.PH
        • Sub-Investigator:
          • william DALFIN, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • People aged between 18 and 30 validating the criteria for UHR or PEP status on the CAARMS scale and having a social functional impact (SOFAS score below 50 or a reduction of more than 30% in the score)

Exclusion Criteria:

  • Previous episode of schizophrenic disorder, schizoaffective disorder or bipolar disorder
  • Previous antipsychotic treatment for more than 12 months
  • Organic mental disorder or intellectual disability
  • Serious suicidal/homicidal risk (but admissible if this risk has been resolved)
  • Insufficient French language skills
  • Adult incapable of giving consent and not under legal protection
  • Protection measure (guardianship/curatorship/court supervision) or under court supervision
  • Person deprived of liberty by judicial or administrative decision (including forced hospitalisation)
  • Persons in a life-threatening emergency
  • Not affiliated to a social security regime

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: MBTP group
Other: MBTP : Mindflulness based training for psychosis
The group-based mindfulness programme is called MBTP (Mindfulness based training for psychosis). The MBTP programme consists of 5 sessions over a period of one month (2 sessions in the first week, then one session a week). Each session lasts approximately 1h30 and is carried out in a group of 5 participants. The sessions cover informal and formal mindfulness tasks, elements of psycho-education on emotions, meditation exercises on emotions, and thought defusion and acceptance tasks. Participants are encouraged to meditate at home between sessions.
No Intervention: TAU group

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Distress related to psychotic symptoms
Time Frame: 3 months
Distress related to psychotic symptoms on the CAARMS scale at the end of therapeutic intervention
3 months
Distress related to psychotic symptoms
Time Frame: 4 months
Distress related to psychotic symptoms on the CAARMS scale at the end of therapeutic intervention
4 months
Distress related to psychotic symptoms
Time Frame: 6 months
Distress related to psychotic symptoms on the CAARMS scale at the end of therapeutic intervention
6 months
Distress related to psychotic symptoms
Time Frame: 9 months
Distress related to psychotic symptoms on the CAARMS scale at the end of therapeutic intervention
9 months

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Intensity of psychotic symptoms
Time Frame: 3 months
Intensity of psychotic symptoms on the CAARMS scale
3 months
Intensity of psychotic symptoms
Time Frame: 4 months
Intensity of psychotic symptoms on the CAARMS scale
4 months
Intensity of psychotic symptoms
Time Frame: 6 months
Intensity of psychotic symptoms on the CAARMS scale
6 months
Intensity of psychotic symptoms
Time Frame: 9 months
Intensity of psychotic symptoms on the CAARMS scale
9 months
Distress related to psychotic symptoms
Time Frame: 3 months
Distress related to psychotic symptoms on the CAARMS scale
3 months
Distress related to psychotic symptoms
Time Frame: 4 months
Distress related to psychotic symptoms on the CAARMS scale
4 months
Distress related to psychotic symptoms
Time Frame: 6 months
Distress related to psychotic symptoms on the CAARMS scale
6 months
Distress related to psychotic symptoms
Time Frame: 9 months
Distress related to psychotic symptoms on the CAARMS scale
9 months
Number of patients making a transition to psychosis
Time Frame: 3 months
Number of patients making a transition to psychosis
3 months
Number of patients making a transition to psychosis
Time Frame: 4 months
Number of patients making a transition to psychosis
4 months
Number of patients making a transition to psychosis
Time Frame: 6 months
Number of patients making a transition to psychosis
6 months
Number of patients making a transition to psychosis
Time Frame: 9 months
Number of patients making a transition to psychosis
9 months
Cognitive functions
Time Frame: 3 months
Cognitive functions measured by the Attentional Performance Tests (APT)
3 months
Cognitive functions
Time Frame: 4 months
Cognitive functions measured by the Attentional Performance Tests (APT)
4 months
Cognitive functions
Time Frame: 6 months
Cognitive functions measured by the Attentional Performance Tests (APT)
6 months
Cognitive functions
Time Frame: 9 months
Cognitive functions measured by the Attentional Performance Tests (APT)
9 months
Cognitive functions
Time Frame: 3 months
Cognitive functions measured by the California Verbal Learning Test (CVLT)
3 months
Cognitive functions
Time Frame: 4 months
Cognitive functions measured by the California Verbal Learning Test (CVLT)
4 months
Cognitive functions
Time Frame: 6 months
Cognitive functions measured by the California Verbal Learning Test (CVLT)
6 months
Cognitive functions
Time Frame: 9 months
Cognitive functions measured by the California Verbal Learning Test (CVLT)
9 months
Anxiety
Time Frame: 3 months
Anxiety measured by the State Trait Anxiety Inventory (STAI)
3 months
Anxiety
Time Frame: 4 months
Anxiety measured by the State Trait Anxiety Inventory (STAI)
4 months
Anxiety
Time Frame: 6 months
Anxiety measured by the State Trait Anxiety Inventory (STAI)
6 months
Anxiety
Time Frame: 9 months
Anxiety measured by the State Trait Anxiety Inventory (STAI)
9 months
Functioning
Time Frame: 3 months
Functioning measured by the Personal and Social Performance Scale (PSP)
3 months
Functioning
Time Frame: 4 months
Functioning measured by the Personal and Social Performance Scale (PSP)
4 months
Functioning
Time Frame: 6 months
Functioning measured by the Personal and Social Performance Scale (PSP)
6 months
Functioning
Time Frame: 9 months
Functioning measured by the Personal and Social Performance Scale (PSP)
9 months
Health-related quality of life (HRQoL)
Time Frame: 3 months
Health-related quality of life (HRQoL) via the SF-12 (12-Item Short Form Health Survey) questionnaire
3 months
Health-related quality of life (HRQoL)
Time Frame: 4 months
Health-related quality of life (HRQoL) via the SF-12 (12-Item Short Form Health Survey) questionnaire
4 months
Health-related quality of life (HRQoL)
Time Frame: 6 months
Health-related quality of life (HRQoL) via the SF-12 (12-Item Short Form Health Survey) questionnaire
6 months
Health-related quality of life (HRQoL)
Time Frame: 9 months
Health-related quality of life (HRQoL) via the SF-12 (12-Item Short Form Health Survey) questionnaire
9 months
Health-related quality of life (HRQoL)
Time Frame: 3 months
Health-related quality of life (HRQoL) via MARS (medication adherence) questionnaire.
3 months
Health-related quality of life (HRQoL)
Time Frame: 4 months
Health-related quality of life (HRQoL) via MARS (medication adherence) questionnaire.
4 months
Health-related quality of life (HRQoL)
Time Frame: 6 months
Health-related quality of life (HRQoL) via MARS (medication adherence) questionnaire.
6 months
Health-related quality of life (HRQoL)
Time Frame: 9 months
Health-related quality of life (HRQoL) via MARS (medication adherence) questionnaire.
9 months
Depressive symptoms
Time Frame: 3 months
Depressive symptoms measured by the Beck Depression Inventory (BDI)
3 months
Depressive symptoms
Time Frame: 4 months
Depressive symptoms measured by the Beck Depression Inventory (BDI)
4 months
Depressive symptoms
Time Frame: 6 months
Depressive symptoms measured by the Beck Depression Inventory (BDI)
6 months
Depressive symptoms
Time Frame: 9 months
Depressive symptoms measured by the Beck Depression Inventory (BDI)
9 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Centre Psychothérapique de Nancy

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Vincent Laprevote, PU.PH, Centre Psychothérapique de Nancy

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 1, 2029

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
April 1, 2029

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 1, 2029

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 6, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 6, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 11, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 25, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 24, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2023-A02766-39
  • RIPH 2023-04 (Other Identifier: centre Psychothérapique de Nancy CPN)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings